Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.